New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily…
Radix Adds World-Class Supply Chain Resilience to Best-In-Class Asset Performance Management
HOUSTON, Jan. 26, 2025 (GLOBE NEWSWIRE) -- Radix, a global technology solutions…
